![John R. Uhrin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Before joining Harbert in 2002, Mr. Uhrin was employed by BioCryst Pharmaceuticals Inc., where he served as Vice President of Corporate Development.
While there, he managed in- and out-licensing of products and technologies to execute research, discovery functions, and commercialization strategies; he coordinated contractual arrangements with corporate partners, and developed and maintained relationships with the biotech industry and academic research institutions.
He was also employed with Genentech, Inc. as Director of Special Markets/Managed Care, where he directed a multi-state domestic and international region, focusing on managed care organizations, insurance companies, HMO's, and Integrated Networks.
Before joining Genentech, Mr. Uhrin spent ten years at Eli Lilly & Company.
Mr. Uhrin received a Bachelor of Science in Pharmacy from the University of North Carolina at Chapel Hill.
Anciens postes connus de John R. Uhrin
| Sociétés | Poste | Fin |
|---|---|---|
HMC-Virginia, Inc.
 HMC-Virginia, Inc. Investment ManagersFinance HMC Virginia invests in companies located in the United States, primarily in Mid-Atlantic, Southeast, Southwest, Midwest. The firm focuses on broad range of sectors. It provides financing for growth stage capital requirements with an investment size of USD 5 - 10 million. It also takes a seat on the board of directors. | Private Equity Investor | 01/02/2010 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Directeur/Membre du Conseil | - |
| BIOCRYST PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Formation de John R. Uhrin
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
13
Relations au 1er degré
5
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
BioCryst Pharmaceuticals, Inc.
 BioCryst Pharmaceuticals, Inc. BiotechnologyHealth Technology Designs and develops oral small-molecule & injectable protein therapeutics | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Eli Lilly & Co.
 Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
HMC-Virginia, Inc.
HMC-Virginia, Inc. Investment ManagersFinance HMC Virginia invests in companies located in the United States, primarily in Mid-Atlantic, Southeast, Southwest, Midwest. The firm focuses on broad range of sectors. It provides financing for growth stage capital requirements with an investment size of USD 5 - 10 million. It also takes a seat on the board of directors. | Finance |
The University of North Carolina at Charlotte
 The University of North Carolina at Charlotte Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
